405 related articles for article (PubMed ID: 29223557)
1. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
3. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.
Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD
J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III Study.
Woo JS; Hong SJ; Cha DH; Kim KS; Kim MH; Lee JW; Jeong MH; Jeong JO; Lee JH; Jeon DS; Cho EJ; Kim SK; Kwan J; Park CG; Lee HY; Hong TJ; Shin J; Youn HJ; Jeon DW; Chung WJ; Jeong JC; Kim CJ
Clin Ther; 2021 Aug; 43(8):1419-1430. PubMed ID: 34332788
[TBL] [Abstract][Full Text] [Related]
6. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
[TBL] [Abstract][Full Text] [Related]
7. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.
Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N
Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377
[TBL] [Abstract][Full Text] [Related]
8. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Jun JE; Jeong IK; Yu JM; Kim SR; Lee IK; Han KA; Choi SH; Kim SK; Park HK; Mok JO; Lee YH; Kwon HS; Kim SH; Kang HC; Lee SA; Lee CB; Choi KM; Her SH; Shin WY; Shin MS; Ahn HS; Kang SH; Cho JM; Jo SH; Cha TJ; Kim SY; Won KH; Kim DB; Lee JH; Lee MK
Diabetes Metab J; 2020 Feb; 44(1):78-90. PubMed ID: 31237134
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.
Med Lett Drugs Ther; 2005 Nov; 47(1221):91. PubMed ID: 16267495
[No Abstract] [Full Text] [Related]
13. Treatment of Chinese Patients with Hypertriglyceridemia with a Pharmaceutical-Grade Preparation of Highly Purified Omega-3 Polyunsaturated Fatty Acid Ethyl Esters: Main Results of a Randomized, Double-Blind, Controlled Trial.
Qi L; Zhang Q; Zheng Z; Pei Z; Mao H; Jiang T; Kazei D; Kahler E; Huo Y
Vasc Health Risk Manag; 2021; 17():571-580. PubMed ID: 34552329
[TBL] [Abstract][Full Text] [Related]
14. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
15. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia.
Durrington PN; Bhatnagar D; Mackness MI; Morgan J; Julier K; Khan MA; France M
Heart; 2001 May; 85(5):544-8. PubMed ID: 11303007
[TBL] [Abstract][Full Text] [Related]
16. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
Davidson MH; Phillips AK; Kling D; Maki KC
Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1045-54. PubMed ID: 25089906
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
[TBL] [Abstract][Full Text] [Related]
18. Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study.
Chantzichristos VG; Agouridis AP; Moutzouri E; Stellos K; Elisaf MS; Tselepis AD
Curr Vasc Pharmacol; 2016; 14(5):474-480. PubMed ID: 27041244
[TBL] [Abstract][Full Text] [Related]
19. N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.
Dogay Us G; Mushtaq S
Lipids Health Dis; 2022 Sep; 21(1):84. PubMed ID: 36050695
[TBL] [Abstract][Full Text] [Related]
20. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
